Professor Yu Zhang: Optimizing the Diagnostic and Treatment Pathway for AML – The Southern Hospital Experience | 9th CSCO Hematologic Oncology Congres

Professor Yu Zhang: Optimizing the Diagnostic and Treatment Pathway for AML – The Southern Hospital Experience | 9th CSCO Hematologic Oncology Congres

2025.07.30
From July 11 to 13, 2025, the 9th Annual Hematologic Oncology Congress hosted by the Chinese Society of Clinical Oncology (CSCO) took place in Harbin. The conference brought together leading experts from China and abroad to discuss key topics in hematologic malignancies, including leukemia, lymphoma, and multiple myeloma. Topics ranged from basic research and innovative drug development to precision medicine strategies and clinical translation. At the conference, Professor Yu Zhang from Southern Hospital of Southern Medical University delivered a compelling presentation titled “Optimizing the Diagnostic and Treatment Pathway for AML at Southern Hospital.” In an exclusive interview with Oncology Frontier – Hematology Frontier, Professor Zhang shared further insights into the hospital’s innovative approaches and practical experiences in managing acute myeloid leukemia (AML).
Professor Lu Yang Explores Latest Advances and Combination Strategies in AR-Targeted Therapy at the 2025 Pujiang Prostate Cancer Congress

Professor Lu Yang Explores Latest Advances and Combination Strategies in AR-Targeted Therapy at the 2025 Pujiang Prostate Cancer Congress

2025.07.23
On June 27, 2025, the Pujiang Prostate Cancer Academic Congress was held in Shanghai, in conjunction with the Annual Meeting of the Chinese Society of Clinical Oncology Prostate Cancer Committee (CSCO-PC), the Prostate Cancer Meeting of the CACA Genitourinary Oncology Committee (CACA-GO), and the Annual Meeting of the Chinese Prostate Cancer Consortium (CPCC). The event gathered leading experts from around the world to discuss cutting-edge developments in prostate cancer treatment. Professor Lu Yang, Department of Urology, West China Hospital of Sichuan University, delivered a keynote presentation on recent advances in targeting the androgen receptor (AR) pathway in prostate cancer, providing important insights for clinical decision-making. He offered a comprehensive overview of the latest innovations in monotherapy, emerging evidence from combination strategies, and the translational potential of new technologies such as PROTACs and epigenetic modulators—while also addressing current challenges and future directions.